Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Trial Details

NCT ID
NCT06908668
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy
  • Neoadjuvant Chemotherapy Combined with Immunotherapy
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Female patients aged between 18 and 70 years old.
  • Pathologically confirmed as invasive breast cancer, with immunohistochemical staining indicating HER2 negativity, as specifically referenced in the…
  • Oncology/College of American Pathologists (ASCO/CAP).
  • Clinical stage II-III, patients who are planned to undergo neoadjuvant treatment to downstage for surgery or who wish to have breast-conserving sur…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →